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ABSTRACT
From December 2006 to December 2016, 1,429 patients enrolled in the Korea human 
immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) Cohort Study 
were investigated. Based on the year of diagnosis, the time interval between HIV diagnosis 
and initiation of antiretroviral therapy (ART) was analyzed by dividing it into 2 years. The 
more recent the diagnosis, the more likely rapid treatment was initiated (P < 0.001) and the 
proportion of patients starting ART on the same day of HIV diagnosis was increased in 2016 
(6.5%) compared to that in 2006 (1.7%). No significant difference in the median values of 
CD4+ cell counts according to the diagnosis year was observed. In the past 20 years, the time 
from the HIV diagnosis to the initiation of ART was significantly reduced. Rapid treatment 
was being implemented at the HIV diagnosis, regardless of CD4+ cell count. Considering the 
perspective “treatment is prevention,” access to more rapid treatment is necessary at the time 
of HIV diagnosis.
Keywords: HIV Infection; Antiretroviral Therapy; Rapid ART; Treatment as Prevention; 
National Cohort
International guidelines for human immunodeficiency virus (HIV) treatment have recently 
highlighted the importance of rapid treatment of HIV infection. It is known that rapid 
antiretroviral therapy (ART) not only reduces the mortality of HIV patients, but also improves 
treatment outcome.1 In addition, a growing number of clinical trials and cohort studies 
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indicate that ART is effective in reducing the transmission of HIV.2 As a result, regional and 
global HIV prevention efforts are increasingly relying on the HIV treatment as prevention 
(TasP) approach to address the HIV epidemic. Treatment as early as possible is also crucial in 
TasP. The approach is expected to play an important role in reducing new HIV infections by 
transmission. Until now, there has been no emphasis on rapid treatment in HIV infection and 
there is no basic data on this situation in Korea. Therefore, we investigated the yearly changes 
in the time from HIV diagnosis to the first ART in Korea.
From December 2006 to December 2016, HIV-infected individuals enrolled in the Korea HIV/
AIDS Cohort Study were evaluated. The Korea HIV/AIDS Cohort Study is a multi-centric, 
prospective study consisting of 15 university hospitals nationwide and managed by the 
Korean Centers for Disease Control and Prevention (KCDC). This cohort has an ongoing 
enrollment of HIV-infected adult patients older than 18 years.
Patient's baseline characteristics were investigated based on the CD4+ cell counts (< 200, 200–500, 
> 500). In addition, the study analyzed the changes in the time taken to start the first ART for 
HIV in the year of HIV diagnosis. The distribution of the time intervals from HIV diagnosis to the 
initiation of ART according to the year of entry into care was plotted to examine the overall pattern. 
Median values and interquartile ranges [IQR] of gender, age, ethnicity, time distribution (< 1 
month, 1 month–1 year, > 1 year) and HIV-RNA titer (copies/mL) at the HIV diagnosis were analyzed 
(Table 1). Data were expressed as median (IQR) or frequencies (%). A P value less than 0.05 was 
considered statistically significant. Statistical analyses were performed using R statistics version 
3.5. The present study protocol was approved by the Institutional Review Board of Kyungpook 
National University College of Medicine (Approval No. 2011-01-048).
There were 1,429 subjects, which included 1,322 (93.2%) men and 97 (6.8%) women. The 
men-to-women ratio was 13.6. The median age at the time of diagnosis was 37 years old. Most 
patients were of Korean ethnicity (1,414; 99%).
Of the total patients, CD4+ cell counts 200 cells/mm3 or more were found in 950 (66.5%) 
and CD4+ cell counts below 200 cells/mm3 were found in 479 (33.5%). Regardless of the year 
at the diagnosis, patients with low CD4+ cell counts < 200 cells/mm3 showed a tendency to 
have shorter time taken from HIV diagnosis to first ART compared with the patients who 
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Table 1. Characteristics of enrolled patients according to CD4+ cell count (cells/mm3)
CD4+ cell count, cells/mm3 < 200 (n = 479) 200–500 (n = 554) > 500 (n = 396) Total (n = 1,429) P value
Gender 0.471
Women 31 (6.5) 43 (7.8) 23 (5.8) 97 (6.8)
Men 448 (93.5) 511 (92.2) 373 (94.2) 1,332 (93.2)
Age, yr 39 (30–47) 35 (28–45) 37 (28–47) 37 (29–46) 0.004
Ethnicity 0.062
Korean 477 (99.6) 544 (98.2) 393 (99.2) 1,414 (99.0)
Othersa 2 (0.4) 10 (1.8) 2 (0.5) 14 (1.0)
Unknown 0 (0.0) 0 (0.0) 1 (0.3) 1 (0.1)
Timeb 57 (23–276) 184 (49–629) 170 (40–904) 115 (34–597) < 0.001
Categorized time < 0.001
< 1 mon 154 (32.2) 83 (15.0) 60 (15.2) 297 (20.8)
1 mon–1 yr 203 (42.4) 233 (42.1) 125 (31.6) 561 (39.3)
> 1 yr 122 (25.5) 238 (43.0) 211 (53.3) 571 (40.0)
HIV-RNA titer, copies/mL 106,000 (24,335–367,000) 25,000 (5,415–84,150) 16,300 (1,650–54,568) 39,668 (7,300–151,500) < 0.001
Values are presented as medians (interquartile range) or number (%).
HIV = human immunodeficiency virus.
aOthers denote non-Korean Asian patients; bDays from HIV diagnosis to first ART.
have CD4+cell counts 200 cells/mm3 or more (Table 1). However, the total median values and 
interquartile ranges (IQR) of CD4+ cell count and HIV-RNA titer were 248 cells/mm3 (IQR 
104–384 cells/mm3) and 39,668 copies/mL (IQR, 7,300–151,500 copies/mL), respectively. 
Moreover, there were no big differences in the median values of CD4+ cell counts and HIV-
RNA titers according to the diagnosis year. It was confirmed that rapid treatment was being 
implemented at the HIV diagnosis, regardless of CD4+ cell count.
Over the years, the time from the HIV diagnosis to the initiation of ART was reduced 
significantly year by year; more than a 5-fold decrease was observed in 2015–2016 compared 
with 2005–2006 (37 days and 201 days, respectively; P < 0.001) (Fig. 1). The more recent the 
diagnosis, the more likely rapid treatment was initiated. For patients recently diagnosed in 
2015–2016, the proportion of patients who began treatment within 2 weeks was still less than 
10% (around 6%). Nevertheless, the proportion of patients starting treatment on the day of 
HIV diagnosis was increased up to 6.5% in 2016. In 2006, the proportion of patients who 
began ART on the same day of diagnosis, within 2 weeks, and within 1 month was measured as 
1.7%, 5.1%, and 22.7%, respectively. After 10 years, when the WHO guidelines were changed, 
the proportion of patients who began ART on the same day of diagnosis, within 2 weeks, and 
within 1 month in 2016 was measured as 6.5%, 12.5%, and 50%, respectively (Fig. 2).
Based on the Korea HIV/AIDS Cohort Study data, we found that the proportion of patients 
who started treatment within a month of diagnosis and the proportion of patients who 
started treatment at the same time have been increasing regardless of CD4+ cell counts 
(following the 2016 WHO guidelines).
In several randomized controlled studies, recommending ART immediately following the 
diagnosis of HIV has been shown to result in both earlier ART initiation and higher rates of 
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Fig. 1. Time from HIV diagnosis to the first antiretroviral therapy according to the diagnosis year.
retention in care and virologic suppression at 10–12 months compared with the standard of 
care without compromising safety.3-5 A previous study showed that in a RAPID program, 
participants had earlier linkage to care, earlier ART initiation, and a shorter time to HIV RNA 
suppression, and high rates of virologic suppression were observed for more than 90% of the 
patients over a median of 1.09 years (1.09, 0–3.92 years) compared with the delayed referral 
group (30 days to 6 months after HIV diagnosis).6 Currently, Rapid Initiation of Treatment 
(RapIT) programs are conducted in many countries around the world. A large HIV clinic in 
Atlanta implemented rapid access to ART on the day of the initial visit. The median time 
required from initial diagnosis to a HIV-1 RNA level of below 200 copies/mL was decreased 
from 67 days to 41 days.7 From 2013 to 2016, a citywide rapid ART program was implemented 
within 5 days of diagnosis with the start of ART at the first care visit in San Francisco, and a 
decreasing pattern was observed in the time from diagnosis to care (38%, from 8 days to 5 
days), care to ART initiation (96%, from 27 days to 1 day), and ART to first suppression (46%, 
from 70 days to 38 days).8,9 In Korea, which does not have a rapid ART program, it has been 
confirmed that it takes around 37 days from diagnosis to treatment in 2015–2016, which is 
around 7 times longer compared with countries with a rapid ART program. It is important 
to develop suitable RAPID programs in Korea so that HIV patients can have access to rapid 
treatment at the same time following HIV diagnosis.
In the Netherlands HIV cohort study, by 2016, the median CD4+ cell count at the start of 
ART was increased to 410 cells/mm3, and the majority of people started ART within 1 month 
of diagnosis.10 In our study, the number of patients who started ART within a month was 
gradually increased up to 50% in 2016 (similar to the Netherlands cohort study). However, 
unlike the study in the Netherlands, a continuous annual increase in the median CD4+ cell 
count was not observed in our study; nevertheless, the proportion of CD4+ cell counts of 500 
or more has been increased. Patients diagnosed in 2015–2016 showed that the proportion of 
CD4+ cell counts less than 200 cells/mm3 still accounts for about 20% and the median value 
and IQR of CD4+ cells were reported to 259 (IQR, 190–363 cells/mm3). It is possible that HIV is 
still not diagnosed early in Korea. A previous study also reported that the number of CD4+ cells 
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Fig. 2. Distribution of time intervals between human immunodeficiency virus diagnosis and antiretroviral therapy 
initiation according to the year of diagnosis.
was reported to be less than 350 cells/mm3, accounting for around 46% of the total Korean HIV/
AIDS cohort patients.11 As early diagnosis is not easy, if diagnosed with HIV, rapid treatment is 
important to prevent the spread of HIV infection and to improve clinical outcomes.12,13
To achieve epidemic control, the annual number of new infections must be below the number 
of deaths among individuals with HIV.14 Because no single approach can reduce the number 
of cases to a level required for epidemic control, improving HIV testing coverage to identify 
HIV-positive individuals as soon as possible after infection and linkage to care should be 
provided with rapid ART.15
In conclusion, in the past 20 years, the time from HIV diagnosis to ART initiation has 
significantly decreased regardless of CD4+ cell counts in Korea. Since the announcement 
of the 2016 WHO guidelines, the rate at which treatment is initiated on the day of diagnosis 
has increased; however, our study found that the proportion of patients who start treatment 
within 1 month of diagnosis was still less than 10% in 2015–2016. Considering the 
perspective “treatment is prevention,” access to rapid treatment is necessary at the time of 
HIV diagnosis. The shorter time to viral suppression will offer both clinical benefits to HIV 
patients and prevention benefits to the community.
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